Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 15,424 as of Tuesday, Sept. 24, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,875 issues advancing vs. 1,030 declining with 132 unchanged. The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. A company within the industry that fell today was Intuitive Surgical ( ISRG), up 1.0%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. BioScrip ( BIOS) is one of the companies pushing the Health Services industry lower today. As of noon trading, BioScrip is down $1.41 (-13.5%) to $9.00 on heavy volume. Thus far, 3.8 million shares of BioScrip exchanged hands as compared to its average daily volume of 864,300 shares. The stock has ranged in price between $8.83-$10.58 after having opened the day at $10.39 as compared to the previous trading day's close of $10.41. BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. BioScrip has a market cap of $750.3 million and is part of the health care sector. Shares are up 2.8% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates BioScrip as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full BioScrip Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.